116 related articles for article (PubMed ID: 36765553)
1. SEOM-GEINO clinical guidelines for grade 2 gliomas (2023).
Vaz-Salgado MÁ; García BC; Pérez IF; Munárriz BJ; Domarco PS; González AH; Villar MV; Caro RL; Delgado MLV; Sánchez JMS
Clin Transl Oncol; 2024 Apr; ():. PubMed ID: 38662171
[TBL] [Abstract][Full Text] [Related]
2. Cancer vaccine strategies for the treatment of diffusely infiltrating gliomas.
Jucht A; Dumont S; Pooley C; Gonzalez Castro LN
Ther Adv Vaccines Immunother; 2023; 11():25151355231206163. PubMed ID: 37886714
[TBL] [Abstract][Full Text] [Related]
3. Advanced imaging in adult diffusely infiltrating low-grade gliomas.
Bulakbaşı N; Paksoy Y
Insights Imaging; 2019 Dec; 10(1):122. PubMed ID: 31853670
[TBL] [Abstract][Full Text] [Related]
4. Preclinical modeling of lower-grade gliomas.
Tang LW; Mallela AN; Deng H; Richardson TE; Hervey-Jumper SL; McBrayer SK; Abdullah KG
Front Oncol; 2023; 13():1139383. PubMed ID: 37051530
[TBL] [Abstract][Full Text] [Related]
5. DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology.
Rahman R; Shi DD; Reitman ZJ; Hamerlik P; de Groot JF; Haas-Kogan DA; D'Andrea AD; Sulman EP; Tanner K; Agar NYR; Sarkaria JN; Tinkle CL; Bindra RS; Mehta MP; Wen PY
Neuro Oncol; 2024 Mar; ():. PubMed ID: 38770568
[TBL] [Abstract][Full Text] [Related]
6. Focus on current and emerging treatment options for glioma: A comprehensive review.
Lucke-Wold B; Rangwala BS; Shafique MA; Siddiq MA; Mustafa MS; Danish F; Nasrullah RMU; Zainab N; Haseeb A
World J Clin Oncol; 2024 Apr; 15(4):482-495. PubMed ID: 38689623
[TBL] [Abstract][Full Text] [Related]
7. Milestones of the last 10 years: CNS cancer.
Marosi C; Preusser M
Memo; 2017; 10(1):18-21. PubMed ID: 28367251
[TBL] [Abstract][Full Text] [Related]
8. A Survey of the Neuro-Oncology Landscape.
Lukas RV; Wu J; Dey M; Buerki RA; Byrne RW; Dohrmann GJ
J Clin Neurol; 2018 Jan; 14(1):8-15. PubMed ID: 29141278
[TBL] [Abstract][Full Text] [Related]
9. Isocitrate dehydrogenase mutations in gliomas: A review of current understanding and trials.
Sharma N; Mallela AN; Shi DD; Tang LW; Abou-Al-Shaar H; Gersey ZC; Zhang X; McBrayer SK; Abdullah KG
Neurooncol Adv; 2023; 5(1):vdad053. PubMed ID: 37287696
[TBL] [Abstract][Full Text] [Related]
10. Therapies for IDH-Mutant Gliomas.
Alshiekh Nasany R; de la Fuente MI
Curr Neurol Neurosci Rep; 2023 May; 23(5):225-233. PubMed ID: 37060388
[TBL] [Abstract][Full Text] [Related]
11. Stalled oligodendrocyte differentiation in IDH-mutant gliomas.
Wei Y; Li G; Feng J; Wu F; Zhao Z; Bao Z; Zhang W; Su X; Li J; Qi X; Duan Z; Zhang Y; Vega SF; Jakola AS; Sun Y; Carén H; Jiang T; Fan X
Genome Med; 2023 Apr; 15(1):24. PubMed ID: 37055795
[TBL] [Abstract][Full Text] [Related]
12. The role of focused ultrasound for pediatric brain tumors: current insights and future implications on treatment strategies.
Chesney KM; Keating GF; Patel N; Kilburn L; Fonseca A; Wu CC; Nazarian J; Packer RJ; Donoho DA; Oluigbo C; Myseros JS; Keating RF; Syed HR
Childs Nerv Syst; 2024 May; ():. PubMed ID: 38702518
[TBL] [Abstract][Full Text] [Related]
13. Potential Molecular Targets in the Treatment of Patients with CNS Tumors.
Pan E
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568623
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma.
Gallus M; Kwok D; Lakshmanachetty S; Yamamichi A; Okada H
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509387
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Models of Low-Grade Gliomas.
Dasgupta P; Balasubramanyian V; de Groot JF; Majd NK
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765553
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
17. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
[TBL] [Abstract][Full Text] [Related]
18. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
Chen SC; Lo CM; Wang SH; Su EC
BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
